Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGAT2 | Q10469 | 1/20 | 0.68 |
| ▸ | PDE7A | Q13946 | 4/20 | 0.44 |
| ▸ | LMNA | P02545 | 4/20 | 0.42 |
| ▸ | TP53 | P04637 | 2/20 | 0.42 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.41 |
| ▸ | ALDH1A2 | O94788 | 6/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.40 |
| ▸ | ALDH1A3 | P47895 | 6/20 | 0.40 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12117147 | 0.88 | MGAT2 (0.63) | MGAT2PDE7ALMNATP53ALDH1A1 | |
| SCHEMBL1312290 | 0.87 | MGAT2 (0.78) | MGAT2PDE7ALMNATP53ALDH1A2 | |
| SCHEMBL12117155 | 0.84 | MGAT2 (0.81) | MGAT2LMNATP53NPY5R | |
| SCHEMBL12117156 | 0.83 | MGAT2 (0.81) | MGAT2LMNATP53ALDH1A2ALDH1A1 | |
| SCHEMBL12117381 | 0.83 | MGAT2 (0.81) | MGAT2NPY5RMEN1KMT2A | |
| SCHEMBL12117210 | 0.83 | MGAT2 (0.85) | MGAT2PDE7ANPY5R | |
| SCHEMBL12117162 | 0.82 | MGAT2 (0.80) | MGAT2TP53NPY5R | |
| SCHEMBL12117154 | 0.82 | MGAT2 (0.75) | MGAT2NPY5R | |
| SCHEMBL12117431 | 0.82 | MGAT2 (0.81) | MGAT2LMNATP53ALDH1A2ALDH1A1 | |
| SCHEMBL12117148 | 0.81 | MGAT2 (0.74) | MGAT2PDE7ALMNATP53ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2398800-A1 | PYRIMIDIN-4(3H)-ONE DERIVATIVES | MSD K.K. (JP) | 2011-12-28 | — | — | EP | claimed |
| US-20110275647-A1 | PYRIMIDIN-4-(3H)-ONE DERIVATIVES | MSD K.K. (JP) | 2011-11-10 | — | — | US | claimed |
| WO-2010095767-A1 | PYRIMIDIN-4(3H)-ONE DERIVATIVES | BANYU PHARMACEUTICAL CO.,LTD. (JP) | 2010-08-26 | — | — | WO | claimed |
| US-20110275647-A1 | PYRIMIDIN-4-(3H)-ONE DERIVATIVES | MSD K.K. (JP) | 2011-11-10 | — | — | US | disclosed |
| US-20110275647-A1 | PYRIMIDIN-4-(3H)-ONE DERIVATIVES | MSD K.K. (JP) | 2011-11-10 | — | — | US | disclosed |
| US-20110275647-A1 | PYRIMIDIN-4-(3H)-ONE DERIVATIVES | MSD K.K. (JP) | 2011-11-10 | — | — | US | disclosed |
| WO-2010095767-A1 | PYRIMIDIN-4(3H)-ONE DERIVATIVES | BANYU PHARMACEUTICAL CO.,LTD. (JP) | 2010-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110275647-A1 | PYRIMIDIN-4-(3H)-ONE DERIVATIVES | ABL1, JAK2, JAK1 | MGAT2 4111/4885PDE7A 1606/4885LMNA 2865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.